



Dr Henning Gädeke
c/o Dr Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 - 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

29th of September 2025

Letter of endorsement

Dear Sir/Madam,

On behalf of Pharco Pharmaceuticals listed in the Trade & Register under Law Of Egypt under number 1358, at Alexandria- Cairo road Km31, Amriya with Vat number 100-133-711 and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU). Pharco Pharmaceuticals is a leading healthcare company based in Egypt and dedicated to improving access to high-quality, affordable medicines worldwide. Our mission aligns strongly with the objectives of the Global Health EDCTP3 JU, particularly in addressing urgent global health challenges through innovation, equitable partnerships, and capacity building in low- and middle-income countries .

As part of our shared vision with the Global Health EDCTP3 JU, Pharco will provide an in-kind contribution to the RAMP project. This contribution will consist of the supply of the Investigational Medicinal Product (IMP), specifically ravidasvir tablets (200 mg) and matching placebo. Pharco will also support packaging and labelling activities according to the needs of the project. This in-kind contribution will enable the implementation of high-quality clinical research in Africa and strengthen evidence generation for effective, accessible treatments, thereby adding direct value to the objectives of the Global Health EDCTP3 JU. The proposed contribution aligns with the Global Health EDCTP3 JU's focus

P. O. Box : 12 Sidi Gaber, Alexandria, Egypt.
Tel. : 2-03-4480130 / 140 / 440 Fax : +2-03-4480730
E-mail : pharco@pharco.com.eg

الإدارة والمصانع : العامرية الكيلو ٣١ طريق الإسكندرية القاهرة الصحراوي
تليفون : ٤٤٠ / ١٤٠ / ٤٤٨٠١٣٠ +٢٠٣- فاكس : ٤٤٨٠٧٣٠ +٢٠٣-
المراسلات : ص.ب. ١٢ سيدى جابر - الإسكندرية - ج.م.ع.

Initial

YMF

on interventions targeting infectious diseases and antimicrobial resistance, while reinforcing equitable access to essential health products in resource-limited settings. Pharco's contribution falls under Objective 1.3 - Sponsor responsibilities, including regulatory submissions, IMP management, documentation, and safety reporting, and more specifically under Task 1.3.2 - Investigational Medicinal Product Management. Pharco will:

- Provide the investigational products (ravidasvir 200 mg tablets and placebo).
- Support packaging and labelling according to protocol requirements.
- Facilitate logistics for procurement and distribution in collaboration with project partners.
- Contribute to documentation and import licensing processes as needed.

We estimate the total value of this in-kind contribution to be EUR 277.5 k€ which corresponds to the cost of production, packaging, and supply of the IMPs over the full duration of the RAMP project, as well as Staff- non Scientific (Including benefits), support functions such as documentation, supervision, Legal, IT, IP overview of our contribution and interactions with partners by Pharco executive officers (please see Table below).

Pharco		
Budget Category	Cost (€) /year	Description
[e.g. Personnel costs] including expertise and logistics	90 k€ + 72 k€ = 162 k€	FTE/month = 1500 persons 5 persons + FTE/month = 2000 3 persons
[e.g. Purchase costs (Travel, Equipment, Other goods, works & services)]	60 k€	Free goods supply for clinical trials: drug and placebo
[e.g. Subcontracting costs]	Not applicable	
[e.g. Financial support to 3 rd parties]	No direct financial support	
Indirect costs (25% applied on Personnel and Purchase costs)	Indirect costs 55.5 k€	25% of Direct costs of 222 k€
Total (€)	277.5 k€	

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP-JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Not least, if the submitted project confirms the clinical and/or public health benefit of using ravidasvir in malaria, Pharco hereby commits itself to work in collaboration with partners of the project to obtain together the WHO prequalification of the combination of ravidasvir with an artemisinin-based combination or any relevant combination of antimalarial agents. Pharco will also make steps to ultimately ensure sustainably of its use in malaria by reducing the final cost to amounts affordable for patients in need.

Yours faithfully,

Date: 29/09/2025

Name: **Yasser Mohammed Fayed**

Position: **Corporate Business Development Director**

Signed by:

Yasser Mohammed

078892C7CB3B4D3...

P. O. Box : 12 Sidi Gaber, Alexandria, Egypt.

Tel. : 2-03-4480130 / 140 / 440

Fax : +2-03-4480730

E-mail : pharco@pharco.com.eg

الإدارة والمصانع : العامرية الكيلو ٣١ طريق الإسكندرية القاهرة الصحراوي

فاكس : +٢٠٣-٤٤٨٠٧٣٠

تليفون : +٢٠٣-٤٤٨٠١٣٠ / ١٤٠ / ٤٤٠

المراسلات : ص.ب. ١٢ سیدی جابر- الإسكندرية - ج.م.ع.